α
AlphaScala
StocksSignalsNEWAlpha ScoreBrokers
Sign InGet Started
α
AlphaScala

Professional trading analysis with publicly tracked portfolios on TipRanks. Real trades, real data.

Markets

ForexStocksCryptoCommodities

Tools

Stock ResearchMarket SignalsAlpha ScoreHedge Funds 13FInsider BuysAgentic TradingAI Broker MatcherBroker ReviewsPortfoliosFree IndicatorsBlogLearn TradingTrading Q&A

Account

Sign InDashboardNewsletterContact UsAdvertise

Legal

AboutEditorial PolicyCorrectionsTerms of ServicePrivacy PolicyRisk Disclaimer

Risk Warning: AlphaScala provides educational content only and is not a financial advisor. Trading and investing involves substantial risk of loss and is not suitable for all investors. Past performance does not guarantee future results. You should consult a licensed financial advisor before making investment decisions. See our full risk disclaimer.

For AI AgentsAlphaScala is agent-ready —skill.md·llms.txt
© 2026 ROGA AI LIMITED · Registered in Gibraltar · Unit G02, Eurocity, Europort Avenue, Gibraltar GX11 1AAAlphaScala — Built with data, not hype.
All Stocks/Healthcare/NUVB

Nuvation Bio Inc.

NUVB
HealthcareBiotechnology Website
Signal SnapshotMarket signals →
Alpha Score
Score pending
Alpha Score appears once the required price and fundamentals data has ingested.
Daily model
Insiders
No recent signal
No recent open-market insider buying or selling is in the current rollup.
Form 4
13F Holder
Marshall Wace
$11.06M reported position; latest action: new.
Institutional holder
Latest Filing
No filing digest
Recent 10-K, 10-Q, and 8-K summaries will appear here when available.
SEC digest
Price ChartPowered by TradingView
Ask about NUVBAI research agent
Top Institutional HoldersFrom 13F filings
FundShares HeldPosition ValueAction (latest Q)
Marshall Wace1.23M$11.06MNEW
D.E. Shaw
David Shaw
876K$7.85MNEW
Citadel
Ken Griffin
614K$5.50MNEW
Point72
Steve Cohen
20K$175.5KNEW
Greenlight Capital
David Einhorn
35K$52.8KNEW
Explore all tracked funds →
About Nuvation Bio Inc.

Nuvation Bio Inc. is a biopharmaceutical company focused on developing innovative therapies for oncology patients. Its primary purpose is to research and advance novel drug candidates targeting various forms of cancer, particularly those for which few treatments currently exist. The company's pipeline is centered on next-generation therapies, including small molecules and targeted drugs designed to enhance and extend the lives of cancer patients. Operating in the highly competitive and scientifically rigorous field of biotechnology, Nuvation Bio Inc. collaborates with leading experts in oncological research to bring promising treatments to clinical trials. Its strategic focus on areas like neuroendocrine tumors and advanced prostate cancer highlights its dedication to addressing unmet medical needs. In the financial markets, Nuvation Bio Inc. holds significance due to its potential impact on the healthcare sector, particularly through the development of breakthrough cancer therapies that could transform treatment paradigms. The company's progress is closely followed by investors and stakeholders interested in the future of cancer treatment innovation.

CEO
Dr. David T. Hung M.D.
Employees
298
Quick Facts
Exchange—
SectorHealthcare
IndustryBiotechnology
Market Cap—
Popular Stocks
AAPL
Apple Inc.
MSFT
Microsoft Corporation
NVDA
NVIDIA Corporation
AMZN
Amazon.com Inc.
GOOGL
Alphabet Inc. Class A
GOOG
Alphabet Inc. Class C
META
Meta Platforms Inc.
TSLA
Tesla Inc.
Key Dates

Earnings calendar coming soon. Subscribe to get notified when NUVB reports next.

Get earnings alerts →